Skip to main content

Research at Alzheimer Society of Canada

1-855-705-4636
  • Find a Research Study
  • FAQs
  • Legal Disclaimer
  • Contact Us
  • Français

Alzheimer Society of Canada

Find a Research Study

IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's (IGC-AD1-P2)

What is this Study about?

The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.

What Will Happen in This Study?

Participant will take the study drug orally once per day.  Planned duration of treatment is 6 weeks.

Who is Eligible to Participate in this Study?

60+
Diagnosis of Alzheimer's disease
Must have a study partner

Get in Touch About this Study

Legal Disclaimer

Any materials or links provided herein are strictly for informational purposes only. The Alzheimer Society of Canada does not endorse nor recommend any of the manufacturers, products or institutions mentioned in any of these links or listings as suitable or appropriate for your particular situation or circumstances and disclaims any liability with respect to representations, warranties, including fitness for an intended particular use or purpose, and all other claims relating thereto, all of which remain strictly with the manufacturer or institution.

In no event shall the Alzheimer Society of Canada or any third parties mentioned on the website be liable for any damage (including, without limitation, incidental and consequential damages for personal injury/wrongful death, lost profits or damages resulting from lost data or business interruption) or personal injury (including death) resulting from the use, misuse or inability to use any activity, product or service mentioned herein, whether based in warranty, contract, tort or any other legal theory.

Everyone considering participating in any activity is encouraged to speak with their own doctor or health-care team before participating in any activity that may impact their health or well-being.

Clinical Trial

Target Population

Person living with Alzheimer’s disease

Target Age Group(s)

41-65, 66+

Study Location

In-Person

Quebec

Douglas Hospital Research Centre

Ontario

Baycrest 

Ontario, Quebec

Recruitment End Date

December 11, 2025
  • Learn more about observational studies
  • Learn more about clinical trials
  • Brain donations
  • More useful links and resources

Alzheimer Society of Canada logo

Alzheimer Society of Canada
20 Eglinton Avenue West, 16th Floor
Toronto, Ontario M4R 1K8
Information and Referral Line: 1-855-705-4636
Email: [email protected]

Charity registration number: 11878 4925 RR0001

Follow us:

  • Find us on Facebook
  • Follow us on Twitter
  • Follow us on Instagram
  • Subscribe to us on YouTube
  • Find us in LinkedIn

©2022 Alzheimer Society of Canada. All rights reserved.